Chimeric antigen receptors (CAR) are engineered fusion proteins designed to target T cells
to antigens expressed on cancer cells. CAR T cells are now an established treatment for …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …

There is a pressing need for allogeneic chimeric antigen receptor (CAR)-immune cell
therapies that are safe, effective and affordable. We conducted a phase 1/2 trial of cord …

Autologous chimeric antigen receptor (CAR) T cell therapies targeting CD19 have high
efficacy in large B cell lymphomas (LBCLs), but long-term remissions are observed in less …

ZUMA-1 demonstrated a high rate of durable response and a manageable safety profile with
axicabtagene ciloleucel (axi-cel), an anti-CD19 chimeric antigen receptor (CAR) T-cell …

The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …

Chimeric antigen receptor (CAR) T‐cell therapy represents a major advancement in
personalized cancer treatment. In this strategy, a patient's own T cells are genetically …

Chimeric antigen receptor (CAR) T cells use re-engineered cell surface receptors to
specifically bind to and lyse oncogenic cells. Two clinically approved CAR-T–cell therapies …

Chimeric antigen receptor (CAR)-T cells have recently emerged as a powerful therapeutic
approach for the treatment of patients with chemotherapy-refractory or relapsed blood …